Bristol-Myers Squibb BMY Yervoy — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's yervoy — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's yervoy — total revenues?
- Bristol-Myers Squibb (BMY) reported yervoy — total revenues of $769M in Q2 2026.
- How has Bristol-Myers Squibb's yervoy — total revenues changed year-over-year?
- Bristol-Myers Squibb's yervoy — total revenues increased by 5.6% year-over-year, from $728M to $769M.
- What is the long-term trend for Bristol-Myers Squibb's yervoy — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's yervoy — total revenues has grown at a 9.4% compound annual growth rate (CAGR), from $2.03B to $2.9B.
- What does yervoy — total revenues mean?
- This metric represents the total global net sales generated by the Yervoy product line, a monoclonal antibody used in immuno-oncology treatments. It reflects the market adoption, pricing power, and clinical demand for this specific therapeutic asset within the company's oncology portfolio. As a key component of the firm's revenue mix, it serves as a critical indicator of the company's competitive position in the checkpoint inhibitor market.